Eton Pharmaceuticals (ETON) Preferred Stock Liabilities (2017 - 2018)

Eton Pharmaceuticals (ETON) reported Preferred Stock Liabilities of $21.2 million for Q3 2018, up 11.35% sequentially from $19.0 million in Q4 2017.

Eton Pharmaceuticals (ETON) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends

Eton Pharmaceuticals (ETON) has 2 years of Preferred Stock Liabilities data on file, last reported at $21.2 million in Q3 2018.

  • For the quarter ending Q3 2018, Preferred Stock Liabilities changed N/A year-over-year to $21.2 million; the trailing twelve-month figure through Sep 2018 stood at $21.2 million (changed N/A YoY), and the FY2017 full-year result was $19.0 million, changed N/A from the prior year.
  • Preferred Stock Liabilities climbed to $21.2 million in Q3 2018, from $19.0 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $21.2 million in Q3 2018 to a low of $19.0 million in Q4 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Eton Pharmaceuticals 1.19 Bn 1.16 Bn 13.10 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2018 21.16 Mn
Dec 31, 2017 19.00 Mn